Millennium Management LLC Acquires 168,072 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Millennium Management LLC lifted its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 73.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 398,451 shares of the company's stock after acquiring an additional 168,072 shares during the period. Millennium Management LLC owned approximately 0.30% of Centessa Pharmaceuticals worth $6,674,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC grew its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $162,000. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after buying an additional 5,316 shares during the period. Ameriprise Financial Inc. bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $320,000. Finally, XTX Topco Ltd increased its holdings in Centessa Pharmaceuticals by 122.9% in the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after buying an additional 12,506 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $16.45, for a total transaction of $98,700.00. Following the transaction, the general counsel now directly owns 105,386 shares of the company's stock, valued at $1,733,599.70. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now directly owns 276,017 shares in the company, valued at approximately $4,606,723.73. This represents a 16.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 175,398 shares of company stock worth $2,551,442. Company insiders own 7.09% of the company's stock.

Analyst Ratings Changes

CNTA has been the topic of several recent analyst reports. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price on the stock. Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price on the stock. Morgan Stanley reissued an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.89.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock traded up $0.12 during midday trading on Thursday, hitting $13.07. 526,648 shares of the company traded hands, compared to its average volume of 653,360. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -8.54 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm's fifty day moving average price is $12.86 and its 200-day moving average price is $15.41. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.15. As a group, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.